<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2021-6.6-1.2</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-3106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОФТАЛЬМОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPHTHALMOLOGY</subject></subj-group></article-categories><title-group><article-title>Активность хориоидальной неоваскуляризации и структура в формате оптической когерентной томографии-ангиографии при возрастной макулярной дегенерации</article-title><trans-title-group xml:lang="en"><trans-title>Choroidal neovascularization activity and structure by optical coherence tomography angiography in age related macular degeneration</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8000-5757</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалевская</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalevskaya</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> доктор медицинских наук, профессор, заведующая кафедрой офтальмологии</p><p>394036, г. Воронеж, ул. Студенческая, 10, Россия </p></bio><bio xml:lang="en"><p>Dr. Sc. (Med.), Professor, Head of the Ophthalmology Department</p><p> </p></bio><email xlink:type="simple">ipkovalevskaya@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4183-2420</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перерва</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pererva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> аспирант кафедры офтальмологии; врач-офтальмолог</p><p>394036, г. Воронеж, ул. Студенческая, 10, Россия </p><p>123098, г. Москва, ул. Маршала Новикова, 23, Россия</p></bio><bio xml:lang="en"><p> Postgraduate at the Ophthalmology Department; Ophthalmologist</p><p>Studencheskaya str. 10, Voronezh 394036, Russian Federation</p><p>Marshala Novikova str. 23, Moscow 123098, Russian Federation</p></bio><email xlink:type="simple">oxana.pererva@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» Минздрава России</institution><country>Russian Federation</country></aff><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» Минздрава России;&#13;
ФГБУ ГНЦ Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution></aff><aff xml:lang="en"><institution>Voronezh State Medical University named after N.N. Burdenko;&#13;
State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>28</day><month>12</month><year>2021</year></pub-date><volume>6</volume><issue>6-1</issue><fpage>12</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ковалевская М.А., Перерва О.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ковалевская М.А., Перерва О.А.</copyright-holder><copyright-holder xml:lang="en">Kovalevskaya M.A., Pererva O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/3106">https://www.actabiomedica.ru/jour/article/view/3106</self-uri><abstract><p>В экономически развитых странах возрастная макулярная дегенерация (ВМД) – лидирующая причина инвалидности по зрению среди населения старшей возрастной группы. Основным критерием для назначения анти-VEGF (vascular endothelial grow factor) терапии при неоваскулярно й ВМД является активность хориоидальной неоваскуляризации (ХНВ), которая определяется её конфигурацией. Продолжаются поиски оптимальных критериев для количественной оценки состояния макулярной области для решения вопроса о назначении анти-VEGF терапии.Цель: повышение эффективности диагностики и лечения ВМД на основе оценки конфигурации сосудистых сетей на платформе «Ключ к диагнозу II».Материал и методы. В исследование включён 341 пациент: 64 % (218 пациентов, 267 глаз) – с сухой формой ВМД; 36 % (123 пациента, 174 глаза) – с влажной. У 56 пациентов (58 глаз) была отмечена активная ХНВ I типа. Группа 1А – активные ХНВ до лечения (9 пациентов, 9 глаз), группа 1Б – неактивные ХНВ после лечения анти-VEGF препаратами (9 пациентов, 9 глаз); контроль – 10 пациентов (10 глаз) без ВМД. Анализ ОКТ-ангио-изображений хориокапилляров включал выделение ХНВ, расчёт её площади, Df, сложности сосудистой сети (ССС).Результаты. Группа 1А: Df – 1,5871 ± 0,05, ССС – 2,29 ± 0,29, площадь – 11734 ± 4866; группа 1Б: Df – 1,6462 ± 0,08, ССС – 1,65 ± 0,18, площадь – 6797 ± 3818; контроль: Df – 1,9167 ± 0,06, ССС – 1, площадь – 0. Статистически значимые различия были выявлены только для ССС (р = 0,0003). Df коррелирует с площадью ХНВ (р = 0,7), вероятно является недостоверным параметром в связи с неполной визуализацией активных ХНВ.Выводы. ССС является количественным биомаркером для определения активности ХНВ 1-го типа у пациентов с ВМД и может служить параметром для обучения свёрточных нейронных сетей для автоматизированного анализа изображений ОКТ-ангиографии на базе платформы «Ключ к диагнозу II».</p></abstract><trans-abstract xml:lang="en"><p>Background. In economically developed countries, age-related macular degeneration (AMD) is the leading cause of visual disability among the population of the older age group. The main criterion for the anti-VEGF treatment of neovascular AMD is the activity of choroidal neovascularization (CNV), which is determined by its confi guration. The search for optimal criteria for quantifying the state of the macular region in order to decide on the appointment of anti-VEGF therapy continues.Aim: improving the effi ciency of diagnosis and treatment of AMD based on the assessment of the configuration of vascular system on the “Key to Diagnosis II” platform.Material and methods. The study included 341 patients: 64 % (218 patients, 267 eyes) with non-neovascular AMD, 36 % (123 patients, 174 eyes) – with neovascular AMD. 56 patients (58 eyes) had active type I CNV. Group 1A – active CNV before treatment (9 patients, 9 eyes), group 1B – non-active CNV after treatment with antiVEGF (9 patients, 9 eyes); control group – 10 patients (10 eyes) without AMD. Analysis of OCT-angio images of choriocapillaries included the isolation of CNV, its area, fractal dimension (Df) and the complexity of the vascular system (CVS) counting.Results. Group 1A: Df – 1.5871 ± 0.05, CVS – 2.29 ± 0.29, area – 11734 ± 4866; group 1B: Df – 1.6462 ± 0.08, CVS – 1.65 ± 0.18, area – 6797 ± 3818; control: Df – 1.9167 ± 0.06, CVS – 1, area – 0. Significant differences were found for CVS (p = 0.0003). Df correlates with the CNV area (p = 0.7) and is probably an unreliable parameter due to incomplete visualization of active CNV.Conclusions. CVS is a quantitative biomarker for determining the activity of type 1 CNV in patients with AMD and can serve as a parameter for convolutional neural networks training for automated analysis of OCT angiography images based on the “Key to Diagnosis II” platform</p></trans-abstract><kwd-group xml:lang="ru"><kwd>возрастная макулярная дегенерация</kwd><kwd>хориоидальная неоваскуляризация</kwd><kwd>анти-VEGF</kwd><kwd>анализ сосудов сетчатки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>age-related macular degeneration</kwd><kwd>choroidal neovascularization</kwd><kwd>antiVEGF</kwd><kwd>retinal vascular analysis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e116. doi: 10.1016/S2214-109X(13)70145-1</mixed-citation><mixed-citation xml:lang="en">Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e116. doi: 10.1016/S2214-109X(13)70145-1</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kovalevskaya MA, Pererva OA. Multilateral analysis of retinal vascular system. Acta Scientifi c Ophthalmology. 2018; 1: 02-05.</mixed-citation><mixed-citation xml:lang="en">Kovalevskaya MA, Pererva OA. Multilateral analysis of retinal vascular system. Acta Scientifi c Ophthalmology. 2018; 1: 02-05.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ковалевская М.А., Аванесова Т.А., Перерва О.А. Локализация макулы для последующей фотограммометрии при ретинопатии недоношенных и других заболеваниях сетчатки. Невские горизонты – 2020: Материалы научной конференции. 2020; 278-279.</mixed-citation><mixed-citation xml:lang="en">Kovalevskaya MA, Avanesova TA, Pererva OA. Localization of the macula for subsequent photogrammetry in retinopathy of prematurity and other retinal diseases. Nevskie gorizonty – 2020: Materialy nauchnoy konferentsii. 2020; 278-279. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ковалевская М.А., Перерва О.А. Роль макулярного интерфейса в диагностике ретинопатии недоношенных и диабетической ангиоретинопатии. Современные технологии в офтальмологии. 2021; 3(38): 363-366. doi: 10.25276/2312-4911-2021-3-363-366</mixed-citation><mixed-citation xml:lang="en">Kovalevskaya MA, Pererva OA. The role of the macular interface in the diagnosis of retinopathy of prematurity and diabetic angioretinopathy. Modern Technologies in Ophthalmology. 2021; 3(38): 363-366. (In Russ.). doi: 10.25276/2312-4911-2021-3-363-366</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: Optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017; 255(7): 1259-1273. doi: 10.1007/s00417-017-3647-4</mixed-citation><mixed-citation xml:lang="en">Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: Optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017; 255(7): 1259-1273. doi: 10.1007/s00417-017-3647-4</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Coscas G, Lupidi M, Coscas F, Français C, Cagini C, Souied EH. Optical coherence tomography angiography during follow-up: Qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therap. Ophthalmic Res. 2015; 54(2): 57-63. doi: 10.1159/000433547</mixed-citation><mixed-citation xml:lang="en">Coscas G, Lupidi M, Coscas F, Français C, Cagini C, Souied EH. Optical coherence tomography angiography during follow-up: Qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therap. Ophthalmic Res. 2015; 54(2): 57-63. doi: 10.1159/000433547</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В., Астахов Ю.С., Коротких С.А., Бобыкин Е.В., Зайцева О.В., Лисочкина А.Б., и др. Протокол выполнения интравитреального введения лекарственных препаратов. Консенсус Экспертного совета по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации «Ассоциация врачей-офтальмологов». Вестник офтальмологии. 2020; 6-2(136): 251-263. doi: 10.17116/oftalma2020136062251</mixed-citation><mixed-citation xml:lang="en">Neroev VV, Astakhov YuS, Korotkikh SA, Bobykin EV, Zaitseva OV, Lisochkina AB, et al. Protocol of intravitreal drug delivery. Consensus of the Expert Council of Retina and Optic Nerve Diseases of the All-Russian Public Organization “Association of Ophthalmologists”. Vestnik oftal’mologii. 2020; 6-2(136): 251-263. (In Russ.). doi: 10.17116/oftalma2020136062251</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Avakian A, Kalina RE, Sage EH, Rambhia AH, Elliott KE, Chuang EL, et al. Fractal analysis of region based vascular change in the normal and non-proliferative diabetic retina. Curr Eye Res. 2002; 24(4): 274-280. doi: 10.1076/ceyr.24.4.274.8411</mixed-citation><mixed-citation xml:lang="en">Avakian A, Kalina RE, Sage EH, Rambhia AH, Elliott KE, Chuang EL, et al. Fractal analysis of region based vascular change in the normal and non-proliferative diabetic retina. Curr Eye Res. 2002; 24(4): 274-280. doi: 10.1076/ceyr.24.4.274.8411</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Masters BR. Fractal analysis of the vascular tree in the human retina. Annu Rev Biomed Eng. 2004; 6: 427-452. doi: 10.1146/annurev.bioeng.6.040803.140100</mixed-citation><mixed-citation xml:lang="en">Masters BR. Fractal analysis of the vascular tree in the human retina. Annu Rev Biomed Eng. 2004; 6: 427-452. doi: 10.1146/annurev.bioeng.6.040803.140100</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kovalevskaiia MA, Ponomareva NI, Pererva OA. Algorithm of improving image quality, diagnosis and morphometry at retinopathy of prematurity. EC Ophthalmology. 2019: 10(6): 471-475.</mixed-citation><mixed-citation xml:lang="en">Kovalevskaiia MA, Ponomareva NI, Pererva OA. Algorithm of improving image quality, diagnosis and morphometry at retinopathy of prematurity. EC Ophthalmology. 2019: 10(6): 471-475.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Serra R, Coscas F, Pinna A, Cabral D, Coscas G, Souied EH. Quantitative optical coherence tomography angiography features of inactive macular neovascularization in age-related macular degeneration. Retina. 2021; 1(41): 93-102. doi: 10.1097/IAE.0000000000002807</mixed-citation><mixed-citation xml:lang="en">Serra R, Coscas F, Pinna A, Cabral D, Coscas G, Souied EH. Quantitative optical coherence tomography angiography features of inactive macular neovascularization in age-related macular degeneration. Retina. 2021; 1(41): 93-102. doi: 10.1097/IAE.0000000000002807</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Sheikh M, Iafe NA, Phasukkijwatana N, Sadda SR, Sarraf D. Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography. Retina. 2018; 38(2): 220-230. doi: 10.1097/IAE.0000000000001628</mixed-citation><mixed-citation xml:lang="en">Al-Sheikh M, Iafe NA, Phasukkijwatana N, Sadda SR, Sarraf D. Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography. Retina. 2018; 38(2): 220-230. doi: 10.1097/IAE.0000000000001628</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Faatz H, Farecki ML, Rothaus K, Gunnemann F, Gutfleisch M, Lommatzsch A, et al. Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in agerelated macular degeneration during anti-VEGF therapy: Evaluation of a new quantitative method. Eye. 2019; 33(9): 1466-1471. doi: 10.1038/s41433-019-0429-8</mixed-citation><mixed-citation xml:lang="en">Faatz H, Farecki ML, Rothaus K, Gunnemann F, Gutfleisch M, Lommatzsch A, et al. Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in agerelated macular degeneration during anti-VEGF therapy: Evaluation of a new quantitative method. Eye. 2019; 33(9): 1466-1471. doi: 10.1038/s41433-019-0429-8</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
